| Title: |
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies |
| Authors: |
Bender Ignacio, Rachel A. 1, 2, 13, 14, ∗; Chew, Kara W. 3, 13; Moser, Carlee 4; Currier, Judith S. 3; Eron, Joseph J. 5; Javan, Arzhang Cyrus 6; Giganti, Mark J. 4; Ritz, Justin 4; Gibbs, Michael 7; Kouekam, Hervé Tchouakam 8; Esser, Mark T. 8; Daar, Eric S. 9; Choudhary, Manish 10; Deo, Rinki 10; Fletcher, Courtney V. 11; Li, Jonathan Z. 10; Hughes, Michael D. 4; Smith, Davey 12, 13; Wohl, David Alain 5, 13 |
| Source: |
In iScience 21 March 2025 28(3) |
| Database: |
ScienceDirect |